Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Betamethasone Valerate

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Phase 1 (1)
Phase 2 (1)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT07205081Phase 1Completed

Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis

NCT04194814Phase 2CompletedPrimary

Skin bioMARkers for Atopic Eczema Therapy Evaluation

Showing all 2 trials

Research Network

Common Treatments

  • Betamethasone Valerate1
  • Crisaborole1
  • Atto37121

Active Sponsors

  • University of Sheffield1
  • Sheffield Teaching Hospitals NHS Foundation Trust1
  • Attovia Therapeutics Inc1

Top Investigators

Related Conditions

  • Atopic Dermatitis Ad1
  • Atopic Eczema1
  • Normal Volunteers1

Activity Timeline